引入非维生素K拮抗剂口服抗凝药后心房颤动卒中预防的改善
研究在瑞典斯德哥尔摩县医疗数据库纳入2012年(n=41008)和2017年(n=49510)记录的心房颤动患者,随访临床结局。口服抗凝药处方比例从51.6%升至73.8%,非维生素K拮抗剂口服抗凝药从0.4%升至34.4%,缺血性卒中发生率从2.01/100人年降至1.17/100人年(发生率比0.58;95%CI 0.52-0.65),大出血发生率(2.59)不变(发生率比1.00;95%CI 0.92-1.09)。
要点
- 口服抗凝药处方从51.6%升至73.8%,CHA2DS2-VASc≥2者达78.7%。
- 缺血性卒中发生率从2.01/100人年降至1.17/100人年(发生率比0.58;95%CI 0.52-0.65)。
- 大出血发生率保持2.59不变(发生率比1.00;95%CI 0.92-1.09)。
核心结论
- 口服抗凝药使用增加与缺血性卒中显著减少相关,且未增加出血率。
- 卒中减少幅度最大见于卒中和出血风险最高的高龄患者。
- 这些发现强烈支持在初级和二级医疗中采纳当前指南的房颤卒中预防推荐。
研究设计与样本
- 基于斯德哥尔摩县医疗数据库(Vårdanalysdatabasen)的真实世界总人群研究。
- 纳入过去5年有房颤诊断记录的所有存活居民,随访2012年(n=41008)和2017年(n=49510)的临床结局。
主要发现
- 口服抗凝药药房申领比例从51.6%升至73.8%,其中CHA2DS2-VASc≥2者达78.7%。
- 非维生素K拮抗剂口服抗凝药申领比例从0.4%升至34.4%。
- 缺血性卒中发生率从2012年2.01/100人年降至2017年1.17/100人年(发生率比0.58;95%CI 0.52-0.65)。
- 大出血发生率(2.59)保持不变(发生率比1.00;95%CI 0.92-1.09),即使在高出血风险者中亦然。
- 泊松回归显示,绝对缺血性卒中减少的10%与口服抗凝药治疗增加相关,27%与所有卒中风险普遍降低相关。
临床怎么用
- 作者认为这些发现强烈支持在初级和二级医疗中采纳当前指南的房颤卒中预防推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- The purpose of this study was to investigate the impact of improved antithrombotic treatment in atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants on the incidence of stroke and bleeding in a real-life total population, including both primary and secondary care. Methods- All resident and alive patients with a recorded diagnosis for atrial fibrillation during the preceding 5 years in the Stockholm County Healthcare database (Vårdanalysdatabasen) were followed for clinical outcomes during 2012 (n=41 008) and 2017 (n=49 510). Results- Pharmacy claims for oral anticoagulants increased from 51.6% to 73.8% (78.7% among those with CHA2DS2-VASc ≥2). Non-vitamin K antagonist oral anticoagulant claims increased from 0.4% to 34.4%. Ischemic stroke incidence rates decreased from 2.01 per 100 person-years in 2012 to 1.17 in 2017 (incidence rate ratio, 0.58; 95% CI, 0.52-0.65). The largest increases in oral anticoagulants use and decreases in ischemic strokes were seen in patients aged ≥80 years who had the highest risk of stroke and bleeding. The incidence rates for major bleeding (2.59) remained unchanged (incidence rate ratio, 1.00; 95% CI, 0.92-1.09) even in those with a high bleeding risk. Poisson regression showed that 10% of the absolute ischemic stroke reduction was associated with increased oral anticoagulants treatment, whereas 27% was related to a generally decreased risk for all stroke. Conclusions- Increased oral anticoagulants use contributed to a marked reduction of ischemic strokes without increasing bleeding rates between 2012 and 2017. The largest stroke reduction was seen in elderly patients with the highest risks for stroke and bleeding. These findings strongly support the adoption of current guideline recommendations for stroke prevention in atrial fibrillation in both primary and secondary care.
引用
- Forslund T, Komen JJ, Andersen M, et al. Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants. Stroke. 2018. PMID: 30354995. doi:10.1161/STROKEAHA.118.021990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。